Analyst Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Gilead Sciences and keeping the price target at $162.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Tazeen Ahmad has given his Buy rating due to a combination of factors tied to Gilead’s strategic expansion and pipeline strength. The planned $7.8bn all-cash acquisition of Arcellx allows Gilead to move from a 50/50 profit split to full ownership of anito-cel, a BCMA CAR-T therapy, which in turn enhances the company’s long-term revenue potential beyond its core HIV portfolio.
Ahmad also notes the FDA’s acceptance of the anito-cel BLA with a late-2026 PDUFA date and assigns a high probability of approval, while projecting peak nominal sales of about $4bn across multiple myeloma settings. In addition, the deal secures access to Arcellx’s D-Domain CAR platform and early pipeline, and with no major U.S. patent cliffs looming plus an unchanged DCF supporting a $162 price objective, she sees a favorable risk‑reward profile that justifies maintaining a Buy recommendation.
Ahmad covers the Healthcare sector, focusing on stocks such as Regeneron, Gilead Sciences, and Ocular Therapeutix. According to TipRanks, Ahmad has an average return of 0.9% and a 54.73% success rate on recommended stocks.
In another report released today, TipRanks – Google also reiterated a Buy rating on the stock with a $172.00 price target.